Cathy Williams

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

William G. Wierda, Thomas J. Kipps, Stephan Stilgenbauer et al. · Journal of Clinical Oncology · 2010 · 587 citations

Pharmacy, Oncology, Pharmacotherapy +17

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Graham Jackson, Faith E. Davies, Charlotte Pawlyn et al. · The Lancet Oncology · 2018 · 340 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial

Gordon Cook, Cathy Williams, Julia Brown et al. · The Lancet Oncology · 2014 · 151 citations · Full text

Medicine, Oncology, Cell Therapy +16

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

Gordon Cook, A. John Ashcroft, David A. Cairns et al. · The Lancet Haematology · 2016 · 149 citations

Medicine, Hematology, Oncology +14

A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

Robert Z. Orlowski, Liana Gercheva, Cathy Williams et al. · American Journal of Hematology · 2014 · 132 citations · Full text

Medicine, Hematology, Pharmacotherapy +16